Great Britain’s national health agency late last year reaffirmed its decision to deny the breakthrough drug Avastin to patients with advanced breast cancer. Just days later, the U.S. Food and Drug Administration (FDA) followed suit, denying treatment — and hope — to the 17,500 American breast cancer patients prescribed Avastin each year.
This is a sign of things to come. Under the new health overhaul law, far too many medical decisions will be made by bureaucrats — not doctors and patients. Read More»